Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Zhaoqing Ding, Vidhu Mathur, Peggy P Ho...
https://pubmed.ncbi.nlm.nih.gov/24493798/Actively Recruiting
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-07-13
50
Participants Needed
1
Research Sites
8 weeks
Total Duration
Researchers are investigating the effects of ganciclovir capsules on patients with refractory moderate-to-severe allergic rhinitis. This study aims to evaluate whether ganciclovir improves nasal symptoms and quality of life, as well as to assess its safety. The research is a randomized, double-blind, placebo-controlled clinical trial conducted at a single center. Participants will be randomly assigned to receive either ganciclovir capsules or placebo capsules for two weeks, alongside daily mometasone furoate nasal spray. The study includes a screening phase, a 14-day treatment phase, and a two-week follow-up phase. During screening, various tests and symptom assessments are conducted to confirm eligibility. The treatment phase involves taking oral capsules twice daily and continuing nasal spray use. Throughout the trial, participants will have nasal symptom scores, nasal secretions, blood samples, and safety tests such as vital signs and liver and kidney function monitored. Researchers will compare changes in symptom scores and quality of life measures from baseline to the end of treatment and follow-up. The overall participation lasts about six weeks, including screening, treatment, and follow-up.
CONDITIONS
Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis
J
Jianjun Chen
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 2 weeks
Participants are screened for eligibility to participate in the trial. This includes nasal symptom assessments, allergy tests, and other medical evaluations.
Duration - 14 days
Participants receive either ganciclovir capsules or placebo capsules twice daily for two weeks, alongside daily mometasone nasal spray.
Daily medication intake with scheduled visits during treatment phase
Duration - 14 days
Participants continue mometasone nasal spray and are monitored for two additional weeks to assess symptom changes and safety after treatment ends.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Zhaoqing Ding, Vidhu Mathur, Peggy P Ho...
https://pubmed.ncbi.nlm.nih.gov/24493798/Pascal Demoly, Moises A Calderon, Thomas Casale...
https://pubmed.ncbi.nlm.nih.gov/23419058/P Demoly, R Jankowski, O Chassany...
https://pubmed.ncbi.nlm.nih.gov/21518040/C S Crumpacker
https://pubmed.ncbi.nlm.nih.gov/8786764/Vidhu Mathur, Ritwik Burai, Ryan T Vest...
https://pubmed.ncbi.nlm.nih.gov/29268096/Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor